Quinlan Paul T sold 2,900 shares of Oruka Therapeutics, Inc. at $92.37 for −$268k on Sep 21, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
General Counsel
General Counsel
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$267,869.81Shares × reported price
Shares traded
2,900Common Stock
Price per share
$92.37Reported price. Read footnotes for ranges.
% of reported position traded
7.25%This security and ownership context
Holdings after
37,095Direct
Trade date
Sep 21, 2026Sell
Filed
Sep 21, 2026, 4:57 PM ET0-day reporting delay
Accession
0000907654-26-000100Code S · Transaction 226850
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 39,995 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 21, 2026Sell3,832$93.32−$357,591.89Trade 226851
Sep 21, 2026Sell601$94.44−$56,760Trade 226852
Sep 21, 2026Sell2,667$95.31−$254,195.77Trade 226853
Sep 21, 2026Option exercise10,000$0.00$0Trade 226854
Sep 21, 2026Option exercise10,000$7.80$78,000Trade 226849
6 transaction rows in this filing. Joint filers share the same rows.

ORKA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ORKA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +16%1w ago +2.7%1d ago +1.7%
Returns since7d −9.8%30d −14%90d180d1y

Footnotes in full

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive. F6: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.